Micregen’s Board of Directors is composed of highly accomplished individuals with extensive and diverse experience in various fields related to business building, biotech science, and management. They bring a wealth of knowledge and expertise to the table, acquired over many years of working in academia, private and public companies. The Board member’s experience includes leading successful business ventures, working with groundbreaking regenerative biotech research and understanding the intricacies of managing complex organisations.
The Board’s collective experience and professional networks allow them to provide invaluable guidance and leadership to the company, ensuring that Micregen is well-positioned to navigate the challenges and capitalise on the opportunities in today’s rapidly changing business landscape.
Barry Sharples
Executive Chairman
Over the last 35 years, Barry has founded and managed several technology companies through to sale and IPO.
In 2012 he was treated as a patient at one of the founding scientist's clinics and subsequently began establishing the strategy to take this extraordinary regenerative technology to a global market before formally founding Micregen together in 2015.
Athan Papadopoulos MD
Managing Director
A medical doctor who specialised in Biopathology. Over 20 years global biopharmaceutical experience, at a CRO, Novartis, Sanofi and Emergex. Holding international roles as Vice President and Chief Medical Officer.
Athan has headed clinical research and overseen development programs in biologics and immunotherapies. He led development of several important medicines until licensure, and initiated programs that advance the science that is the foundation of medicine.
Steve Ray, PhD
Chief Scientist
Former Senior Lecturer in Acute & Emergency Care at Oxford Brookes University, Professor of Neuroscience at the Carrick Institute Florida, served as International Scientific Advisor to major South African and Swiss stem cell clinics and cell banks.
Steve has extensive experience in the clinical application of stem cell secretomes that extends over twenty-five years. He has presented over one hundred papers at international scientific conferences, with nineteen as the keynote speaker. He has already translated his research through to proven clinical practice.
Jim Curtis
Commercial Director
Jim is a serial entrepreneur with a track record of success in the pharmaceutical industry. He has more than 35 years pharmaceutical industry experience.
Jim has led both Commercial and Research and Development teams across several pharma organisations. He has a demonstrable record of accomplishment of success in Clinical Research, Life Sciences, and Strategic Planning. Jim was a Founding Director of the Clinigen Group, a £1B market capitalisation specialist pharmaceutical and supply company where he was Head of Business Development at the time of the IPO.
Joanne Kelley
Business Development Director
Jo is a senior biopharmaceutical business development leader with extensive global commercial and general management experience and an outstanding record of strategy development, deal preparation and execution. She enjoyed a long and successful career with AstraZeneca, with a significant portion of her career working in business development. Her last role was VP Business Development - Head of Transactions.
Jo has diverse experience in leading buy and sell life sciences deals, including M&A, licensing, collaboration, and divestments. Her track record includes leading transformational, high-value transactions for AstraZeneca.
Cary Depel, BSc LLM
Director of Regulation & Risk Management
A qualified USA Lawyer & UK Solicitor with an accounting, finance and risk management background, Cary has held positions of Compliance Director and Chief Risk Officer in the UK and USA across several sectors, including biotech and medical device manufacturing.
He is a former Fellow and Chairman of the Institute of Risk Management.
Peter Ormerod
Non-Exec Director
Peter built his family business to an exit with over 400 shops nationwide, which was recognised as the largest Hearing Aid and Audiology provider in the UK. He was also instrumental in the successful sale of the business to the Swiss Sonova Group and the subsequent part sale of the business to Boots the Chemist, including overseeing the rebrand to Boots Hearingcare, which he went on to chair.
Peter was also actively involved in the regulation and governance of the hearing sector, a member of the Hearing Aid Council, the government regulator at that time and subsequently a panel member of the Health and Care Professions Council. Peter continues to Chair the National Community Hearing Association. In addition to his non-exec advisory role, Peter Chairs the Micregen remuneration Committee.